Covariates

Renal failure

Days of hospitalizations

Death

OR

95% CI

p value

OR

95% CI

p value

OR

95% CI

p value

Clinical pharmacologist consultation

1.7

0.3 - 4.6

0.4

3.77

1.3 - 6.4

0.005

0.73

0.31 - 1.71

0.6

Acceptance of clinical pharmacologist recommendation

−0.78

−14.59 - 13.03

0.9

4.88

−2.14 - 11.88

0.2

3.94

−4.94 - 12.82

0.4

Previous exposure to aminoglycosides

14.2

2.39 - 85.51

0.004

0.26

1.3 - 2.33

0.8

Amikacin courses on high dose

0.21

0.04 - 1.04

0.6

3.14

−0.87 - 7.12

0.1

0.25

0.08 - 10.2

0.82

Amikacin courses more than 5 days

0.36

0.08 - 1.51

0.08

0.07

0.4 - 2.45

0.87

Amikacin high serum TDM level

1.01

0.71 - 12.17

0.12

−0.02

−1.23 - 0.08

0.7

0.26

0.19 - 8.95

0.78

Renal failure

−3.94

−8.97 - 1.09

0.1

2.8

6.78 - 37.8

<0.001

Amikacin Adverse Effects (AAEs)

0.5

0.14 - 1.79

0.3

6.24

−4.88 - 17.35

0.2

Hemodynamic instability and sepsis*

31.3

2.89 - 336.99

0.005

8.59

3.49 - 18.5

0.001

2.5

2.05 - 38.65

0.001

Pneumonia

3.94

−4.94 - 12.82

0.38

9.2

6.06 - 12.25

<0.001

3.6

1.59 - 8.11

0.002

Use of cardiovascular drugs

4.8

1.33 - 17.52

0.01

Number hospitalizations without fluids administration

0.22

0.48 - 176.62

0.14